Safety alertSource: FDA Drug Enforcement Reports
Class II recall: ACCORD HEALTHCARE, INC.: Levothyroxine Sodium Tablets, USP, 200 mcg (0.2 mg), packaged in a) 90-count bot
FDA has classified as Class II a recall of Levothyroxine Sodium Tablets, USP, 200 mcg (0.2 mg), packaged in 90-count and 1000-count bottles, manufactured by Intas Pharmaceuticals for Accord Healthcare, Inc. The recall was issued due to the product being subpotent, according to the FDA notice.
Most relevant for: Patients prescribed levothyroxine 200 mcg from the affected lots for hypothyroidism management.
Read the original at FDA Drug Enforcement ReportsSummary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.
Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.
Specialties
More otolaryngology (ent) updates
- Updated AAO-HNS Guideline Revises Tinnitus Evaluation and ManagementOct 1, 2026
- Updated AAO-HNSF Guideline Sets Evidence-Based Tinnitus Management StepsOct 1, 2026
- Revision Rate for Inferior Turbinate Reduction Found to Be 4.3%Sep 30, 2026
- Systematic review finds sex differences in OSA diagnostic parametersSep 29, 2026
- Racial disparities found in facial paralysis diagnosis and treatmentSep 29, 2026